Abstract:While monospecific antibodies have long been the foundational offering of protein therapeutics, recent advancements in antibody engineering have allowed for the development of far more complex antibody structures. Novel molecular format (NMF) proteins, such as bispecific antibodies (BsAbs), are structures capable of multispecific binding, allowing for expanded therapeutic functionality. As demand for NMF proteins continues to rise, biomanufacturers face the challenge of increasing bioreactor process productivity while simultaneously maintaining consistent product quality. This challenge is exacerbated when producing structurally complex proteins with asymmetric modalities, as seen in NMFs. In this study, the impact of a high inoculation density (HID) fed-batch process on the productivity and product quality attributes of two CHO cell lines expressing unique NMFs, a monospecific antibody with an Fc-fusion protein and a bispecific antibody, compared to low inoculation density (LID) platform fed-batch processes was evaluated. It was observed that an intensified platform fed-batch process increased product concentrations by 33 and 109% for the two uniquely structured complex proteins in a shorter culture duration while maintaining similar product quality attributes to traditional fed-batch processes.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the effects of high - inoculum - density (HID) fed - batch processes on the productivity and product quality of two Chinese hamster ovary (CHO) cell lines expressing unique novel molecular format (NMF) proteins. Specifically, the paper mainly focuses on the following issues: 1. **Increasing productivity**: With the increasing demand for novel molecular format (NMF) proteins such as complex antibody structures (e.g., bispecific antibodies, BsAbs), one of the main challenges faced by biomanufacturers is how to significantly increase the productivity of bioreactors while shortening the culture time. The traditional low - inoculum - density (LID) fed - batch process can no longer meet this need, so more efficient processes need to be explored. 2. **Maintaining product quality**: Although the improvement of productivity is crucial, ensuring the consistency of product quality is equally important. Especially for NMF proteins with complex structures, problems such as incorrect chain pairing, aggregation, and fragmentation may lead to a decline in product quality. Therefore, it is very important to study whether the HID fed - batch process can maintain product quality similar to that of the traditional LID process while increasing productivity. 3. **Addressing the special challenges of NMF production**: NMF proteins are prone to chain - pairing errors and other quality problems due to their structural complexity and asymmetry. These characteristics make the production of NMF proteins more challenging than that of traditional monoclonal antibodies (mAbs). Therefore, this study also explores the applicability and potential advantages of the HID fed - batch process in the production of such complex molecules. ### Specific content of the study To answer the above questions, the researchers compared the performance of two CHO cell lines expressing different NMF proteins under HID and LID fed - batch processes. The two NMF proteins are: - A monospecific antibody with an Fc - fusion protein - A bispecific antibody (BsAb) formatted using CrossMAb™ technology The research results show that the HID fed - batch process significantly increased the product concentration within a shorter culture time (by 33% and 109% respectively), while maintaining product quality attributes similar to those of the traditional LID process. This provides a valuable reference for future large - scale production of NMF proteins. ### Key conclusions - The HID fed - batch process can significantly increase the productivity of NMF proteins. - Under HID conditions, the key product quality attributes (such as chain pairing, aggregation, purity, charge variants, and glycosylation) are similar to those of the product under LID conditions. - The HID process can reach higher cell density and product concentration in a shorter time, thereby increasing the space - time yield (STY). Through this study, the researchers provide a possible solution for the biopharmaceutical industry to address the challenges faced in NMF protein production and provide a scientific basis for future process optimization.

Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins

An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers

Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production

Improving product quality and productivity of bispecific molecules through the application of continuous perfusion principles

Fed‐batch performance profiles for mAb production using different intensified N − 1 seed strategies are CHO cell‐line dependent

Developing the biofacility of the future based on continuous processing and single-use technology

Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturing

A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing

Sequence and Configuration of a Novel Bispecific Antibody Format Impacts Its Production Using Chinese Hamster Ovary (CHO) Cells

Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture

Proteomic Profiling of IgG1 Producing CHO Cells Using LC/LC-SPS-MS3: The Effects of Bioprocessing Conditions on Productivity and Product Quality

Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study

Process performance and product quality in an integrated continuous antibody production process

Fiber chromatographic enabled process intensification increases monoclonal antibody product yield

Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture

Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach

Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody

Design and operation of a continuous integrated monoclonal antibody production process

Stepwise Cell Culture Process Intensification for High-productivity and Cost-effective Commercial Manufacturing of a Mabcalin TM Bispecifics

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO pools

Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors